Form 4: Invivyd, Inc. Executive Timothy Edward Lee Granted Stock Options

Chief Commercial Officer Timothy Edward Lee of Invivyd, Inc. was granted stock options to purchase 600,000 shares of common stock.

Summary

• Timothy Edward Lee, Chief Commercial Officer of Invivyd, Inc., was granted stock options on June 5, 2024.
• The options allow Lee to purchase 600,000 shares of Invivyd's common stock at an exercise price of $1.76 per share.
• The options vest over a four-year period, with 25% vesting on June 5, 2025, and the remaining 75% vesting monthly over the subsequent three years, contingent upon continuous service.
• The options expire on June 4, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the executive's role and the company's future.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates